WO2002053185A3 - Anti-inflammatory use of polycationic compounds - Google Patents

Anti-inflammatory use of polycationic compounds Download PDF

Info

Publication number
WO2002053185A3
WO2002053185A3 PCT/EP2002/000071 EP0200071W WO02053185A3 WO 2002053185 A3 WO2002053185 A3 WO 2002053185A3 EP 0200071 W EP0200071 W EP 0200071W WO 02053185 A3 WO02053185 A3 WO 02053185A3
Authority
WO
WIPO (PCT)
Prior art keywords
polycationic compounds
inflammatory use
medicament
preparation
inflammatory
Prior art date
Application number
PCT/EP2002/000071
Other languages
French (fr)
Other versions
WO2002053185A2 (en
Inventor
Karen Lingnau
Alena Egyed
Walter Schmidt
Michael Buschle
Sonja Grill
Original Assignee
Intercell Biomedizinische Forschungs & Entwicklungs Gmbh
Cistem Biotechnologies Gmbh
Karen Lingnau
Alena Egyed
Walter Schmidt
Michael Buschle
Sonja Grill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2001/000087 external-priority patent/WO2001054720A1/en
Application filed by Intercell Biomedizinische Forschungs & Entwicklungs Gmbh, Cistem Biotechnologies Gmbh, Karen Lingnau, Alena Egyed, Walter Schmidt, Michael Buschle, Sonja Grill filed Critical Intercell Biomedizinische Forschungs & Entwicklungs Gmbh
Priority to US10/250,777 priority Critical patent/US20040081655A1/en
Priority to EP02702238A priority patent/EP1347776A2/en
Priority to JP2002554134A priority patent/JP2004519453A/en
Priority to CA002433967A priority patent/CA2433967A1/en
Publication of WO2002053185A2 publication Critical patent/WO2002053185A2/en
Publication of WO2002053185A3 publication Critical patent/WO2002053185A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the use of a polycationic compound for the preparation of a medicament for treating or preventing inflammation and for the preparation of a medicament with reduced inflammatory potential.
PCT/EP2002/000071 2001-01-05 2002-01-07 Anti-inflammatory use of polycationic compounds WO2002053185A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/250,777 US20040081655A1 (en) 2001-01-05 2002-01-07 Methods and compositions comprising polycationic compounds
EP02702238A EP1347776A2 (en) 2001-01-05 2002-01-07 Anti-inflammatory use of polycationic compounds
JP2002554134A JP2004519453A (en) 2001-01-05 2002-01-07 Applications of polycationic compounds
CA002433967A CA2433967A1 (en) 2001-01-05 2002-01-07 Anti-inflammatory use of polycationic compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP0100087 2001-01-05
PCT/EP2001/000087 WO2001054720A1 (en) 2000-01-28 2001-01-05 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
ATA670/01 2001-04-25
AT6702001 2001-04-25

Publications (2)

Publication Number Publication Date
WO2002053185A2 WO2002053185A2 (en) 2002-07-11
WO2002053185A3 true WO2002053185A3 (en) 2002-10-31

Family

ID=25608381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000071 WO2002053185A2 (en) 2001-01-05 2002-01-07 Anti-inflammatory use of polycationic compounds

Country Status (3)

Country Link
EP (1) EP1347776A2 (en)
JP (1) JP2004519453A (en)
WO (1) WO2002053185A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533855A (en) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト An antigen encoded by another reading frame from a pathogenic virus.
US7378234B2 (en) 2002-09-13 2008-05-27 Intercell Ag Method for isolating hepatitis C virus peptides
JP2006521321A (en) * 2003-03-24 2006-09-21 インターツェル・アクチェンゲゼルシャフト Use of alum and Th1 immune response inducing adjuvants to promote immune responses
DE602004029657D1 (en) 2003-03-24 2010-12-02 Intercell Ag IMPROVED VACCINES
JPWO2007013613A1 (en) 2005-07-29 2009-02-12 サントリー株式会社 Composition comprising fucoidan or fucoidan hydrolysis product and immunostimulatory material
WO2011034583A2 (en) 2009-09-16 2011-03-24 Duke University Inhibition of endosomal toll-like receptor activation
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (en) * 1968-05-31 1972-09-20
WO1997010840A1 (en) * 1995-09-18 1997-03-27 Hisamitsu Pharmaceutical Co., Inc. Anti-inflammatory antisense drug
WO1997030721A1 (en) * 1996-02-24 1997-08-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition for immunomodulation based on peptides and adjuvants
WO2000000214A2 (en) * 1998-06-26 2000-01-06 N.V. Nutricia Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
JP2000256196A (en) * 1999-03-05 2000-09-19 Pias Arise Kk Anti-inflammatory and anti-allergic medicine
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2001034206A2 (en) * 1999-11-09 2001-05-17 Cmic Co., Ltd. Nucleic acid-containing complex
WO2001093903A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Antigenic composition comprising a polycationic peptide and inosine and cytosine
WO2001093905A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (en) * 1968-05-31 1972-09-20
WO1997010840A1 (en) * 1995-09-18 1997-03-27 Hisamitsu Pharmaceutical Co., Inc. Anti-inflammatory antisense drug
WO1997030721A1 (en) * 1996-02-24 1997-08-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition for immunomodulation based on peptides and adjuvants
WO2000000214A2 (en) * 1998-06-26 2000-01-06 N.V. Nutricia Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
JP2000256196A (en) * 1999-03-05 2000-09-19 Pias Arise Kk Anti-inflammatory and anti-allergic medicine
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2001034206A2 (en) * 1999-11-09 2001-05-17 Cmic Co., Ltd. Nucleic acid-containing complex
WO2001093903A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Antigenic composition comprising a polycationic peptide and inosine and cytosine
WO2001093905A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199718, Derwent World Patents Index; Class B04, AN 1997-202616, XP002203222 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 12 3 January 2001 (2001-01-03) *

Also Published As

Publication number Publication date
WO2002053185A2 (en) 2002-07-11
JP2004519453A (en) 2004-07-02
EP1347776A2 (en) 2003-10-01

Similar Documents

Publication Publication Date Title
AU2002233092A1 (en) Reduction or prevention of pdt related inflammation
AU2002356759A1 (en) 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
AU2002341729A1 (en) Substituted pyrazolyl compounds for the treatment of inflammation
AU2003257666A1 (en) COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
EP1193270A3 (en) Pyrrolobenzodiazepines
AU2002356871A1 (en) Heteroaromatic carboxamide derivatives for the treatment of inflammation
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
MXPA03008045A (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors.
AU2003291480A1 (en) Composition for the prevention and treatment of inflammation of the ear
AU2046900A (en) Methods and compositions for prevention and treatment of restenosis with non-steroidal anti-inflammatory drugs
EP1439839B8 (en) A combination comprising combretastatin and anticancer agents
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
AU2001253749A1 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
WO2002053185A3 (en) Anti-inflammatory use of polycationic compounds
WO2002062322A3 (en) Glycine betaine and its use as anti-hemorrhagic agent
WO2003061572A8 (en) Anti-inflammatory formulations
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
WO2003017922A3 (en) Use of substances with oxytocin activity for the preparation of a pharmaceutical composition against inflammation
WO2003020304A3 (en) Inflammation modulatory compound comprising an endomorphin
NO20022000D0 (en) 6-Methoxy-2-naphthylacetic acid prodrug compositions for the treatment of inflammation
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU2002212281A1 (en) Anti-inflammatory active ingredients
AU2002212489A1 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002235820

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2433967

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002554134

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002702238

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002702238

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10250777

Country of ref document: US